153results about "Saccharide with acyclic radicals" patented technology

The present invention provides an improved process for preparing β-D and β-L 2′-C-methyl-nucleosides and 2′-C-methyl-3′-O-ester nucleosides.

The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

A monomer useful in prepaπng therapeutic compounds includes a diversity element which potentially binds to a target molecule with a dissociation constant of less than 300 11 M and a linker element connected to the diversity element The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to said diversity element, and is capable of forming a reversible covalent bond or noncovalent interaction with a binding partner of the linker element The monomers can be covalently or non-covalently linked together to form a therapeutic multimer or a precursor thereof

Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a compound capable of increasing the quantity of N-acetylneuraminic acid in cells. Examples of the compound to be contained in the therapeutic pharmaceutical agent include N-acetylneuraminic acid, an intermediate produced downstream from N-acetylmannosamine in an N-acetylneuraminic acid biosynthesis pathway, an N-acetylneuraminic acid derivative, an N-acetylmannosamine derivative, an N-acetylneuraminic acid-containing compound, an N-acetylneuraminic acid derivative-containing compound, an N-acetylmannosamine-containing compound, an N-acetylmannosamine derivative-containing compound, an inhibitor of a degrading enzyme for N-acetylneuraminic acid, an inhibitor of a degrading enzyme for N-acetylmannosamine, an inhibitor of a degrading enzyme for the intermediate, and others.

The invention discloses a method for preparing an Amadori compound by virtue of a temperature-variable water phase. According to a principle that cysteine can be combined with an Amadori rearrangement product (ARP) so as to inhibit the brown stain of Maillard reaction, water is taken as a solvent, cysteine is taken as a tracer agent, amino acid and sugar are heated under a certain condition to react, an intermediate is prepared in a water phase under an intermediate formation critical condition determined by virtue of the temperature-variable Maillard reaction, and after the reaction is finished, reduced pressure vaporization is carried out at a low temperature to remove moisture, so as to obtain an ARP solid product. According to a determination method of the critical condition formed by an ARP water phase, only a spectrophotometer is adopted, so that the operation is simple, the cost is low, and the application value is relatively high. According to a water phase synthesis technique disclosed by the invention, the production cost of the ARP is effectively lowered, the industrial requirements of environmental friendliness and sustainability are met; and meanwhile, the obtained ARP product is low in volatility and good in storage stability and has relatively high superiority, and the controllable formation of flavor processing can be realized.

Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling.

This invention relates to crystals comprising apo-LsrB and holo-LsrB. The structure of holo-LsrB identifies a tetrahydroxytetrahydrofuran derived from 4,5-dihydroxy-2,3-pentanedione (DPD) as the active autoinducer-2 (AI-2) molecule in Salmonella typhimurium. The X-ray crystallographic data can be used in a drug discovery method. Additionally the invention provides AI-2 analogs based on this discovery as well as pharmaceutical compositions containing those analogs.

The invention discloses an aminoketose organic steel bar corrosion inhibitor. The aminoketose organic steel bar corrosion inhibitor is prepared by carrying out Amadori rearrangement reaction on aldoses and amines. The aldoses comprise glucose, galactose and mannitose, and have the advantages of wide sources and environment friendliness; and the amines are disclosed in the specification, wherein R1 and R2 are independently selected from C1-C15 straight-chain, branched-chain, cyclic alkyl, aralkyl, aryl, alkenyl, ether alkyl, amino alkyl, alkyl alcohol, alkylamine, alkyl carboxylic acid or hydrogen atom; R1 and R2 can form a ring; and R1 and R2 can not be the hydrogen atom at the same time. The synthesis technique is simple. The prepared corrosion inhibitor has the characteristics of high corrosion inhibition efficiency and environment friendliness, and has obvious application value and broad market prospects.